Abstract
One of existing strategies to engineer active antibody is to link V H and V L domains via a linker peptide. How the composition, length, and conformation of the linker affect antibody activity, however, remains poorly understood. In this study, a dual approach that coordinates molecule modeling, biological measurements, and affinity evaluation was developed to quantify the binding activity of a novel stable miniaturized anti-CD20 antibody or single-chain fragment variable (scFv) with a linker peptide. Upon computer-guided homology modeling, distance geometry analysis, and molecular superimposition and optimization, three new linker peptides PT1, PT2, and PT3 with respective 7, 10, and 15 residues were proposed and three engineered antibodies were then constructed by linking the cloned V H and V L domains and fusing to a derivative of human IgG1. The binding stability and activity of scFv-Fc chimera to CD20 antigen was quantified using a micropipette adhesion frequency assay and a Scatchard analysis. Our data indicated that the binding affinity was similar for the chimera with PT2 or PT3 and ~24-fold higher than that for the chimera with PT1, supporting theoretical predictions in molecular modeling. These results further the understanding in the impact of linker peptide on antibody structure and activity.
Similar content being viewed by others
References
Alfthan, K., K. Takkinen, D. Sizmann, H. Soderlund, and T. T. Teeri. Properties of a single-chain antibody containing different linker peptides. Protein Eng. 8:725–731, 1995.
Alzari, P. M., M. B. Lascombe, and R. J. Poljak. Three-dimensional structure of antibodies. Ann. Rev. Immunol. 6:555–580, 1988.
Atwell, J. L., L. A. Pearce, M. Lah, L. C. Gruen, A. A. Kortt, and P. J. Hudson. Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase. Mol. Immunol. 33:1301–1312, 1996.
Bird, R. E., J. W. Jacobson, S. Johnson, B. M. Kaufman, S. M. Lee, T. Lee, S. H. Pope, G. S. Riordan, and M. Whitlow. Single-chain antigen-binding proteins. Science 242:423–426, 1988.
Chesla, S. E., P. Selvaraj, and C. Zhu. Measuring two-dimensional receptor-ligand binding kinetics by micropipette. Biophys. J. 75:1553–1572, 1998.
Davies, G. M., S. Bosze, F. Hudecz, M. R. Price, and S. J. Tendler. Characterisation of a recombinant Fv fragment of anti-MUC1 antibody HMFG1. Cancer Lett 82:179–184, 1994.
Du, J., H. Wang, C. Zhong, B. Peng, M. Zhang, B. Li, S. Huo, Y. Guo, and J. Ding. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J. Biol. Chem. 282:15073–15080, 2007.
Dumaswala, U. J., M. J. Wilson, T. Jose, and D. L. Daleke. Glutamine- and phosphate-containing hypotonic storage media better maintain erythrocyte membrane physical properties. Blood 88:697–704, 1996.
Feng, J. N., Z. G. Xie, N. Guo, and B. F. Shen. Design and assembly of anti-CD16 ScFv antibody with two different linker peptides. J. Immunol. Meth. 282:33–43, 2003.
Geuijen, C. A. W., M. Clijsters-van der Horst, F. Cox, P. M. L. Rood, M. Throsby, H. H. J. Backus, E. van Deventer, A. M. Kruisbeek, J. Goudsmit, and J. de Kruif. Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery. J. Immunol. Meth. 302:68–77, 2005.
Glockshuber, R., M. Malia, I. Pfitzinger, and A. Pluckthun. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29:1362–1367, 1990.
Golay, J. T., E. A. Clark, and P. C. Beverley. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J. Immunol. 135:3795–3801, 1985.
Green, C. E., D. N. Pearson, N. B. Christensen, and S. I. Simon. Topographic requirements and dynamics of signaling via L-selectin on neutrophils. Am. J. Physiol. Cell Physiol. 284:C705–C717, 2003.
Hoedemaeker, F. J., T. Signorelli, K. Johns, D. A. Kuntz, and D. R. Rose. A single chain Fv fragment of P-glycoprotein-specific monoclonal antibody C219. Design, expression, and crystal structure at 2.4 A resolution. J. Biol. Chem. 272:29784–29789, 1997.
Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61–68, 1989.
Huang, J., J. Chen, S. E. Chesla, T. Yago, P. Mehta, R. P. McEver, C. Zhu, and M. Long. Quantifying the effects of molecular orientation and length on two-dimensional receptor–ligand binding kinetics. J. Biol. Chem. 279:44915–44923, 2004.
Huston, J. S., D. Levinson, M. Mudgett-Hunter, M. S. Tai, J. Novotny, M. N. Margolies, R. J. Ridge, R. E. Bruccoleri, E. Haber, and R. Crea. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA. 85:5879–5883, 1988.
Huston, J. S., J. McCartney, M. S. Tai, C. Mottola-Hartshorn, D. Jin, F. Warren, P. Keck, and H. Oppermann. Medical applications of single-chain antibodies. Int. Rev. Immunol. 10:195–217, 1993.
Kofler, R., and G. Wick. Some methodologic aspects of the chromium chloride method for coupling antigen to erythrocytes. J. Immunol. Meth. 16:201–209, 1977.
Kortt, A. A., O. Dolezal, B. E. Power, and P. J. Hudson. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. 18:95–108, 2001.
Kortt, A. A., R. L. Malby, J. B. Caldwell, L. C. Gruen, N. Ivancic, M. C. Lawrence, G. J. Howlett, R. G. Webster, P. J. Hudson, and P. M. Colman. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. Eur. J. Biochem. 221:151–157, 1994.
Li, B., J. Chen, and M. Long. Measuring binding kinetics of surface-bound molecules using surface plasmon resonance technique. Anal. Biochem. 377:195–201, 2008.
Li, A. L., Y. Li, Y. X. Sun, M. Yu, J. S. Guo, and B. F. Shen. Studies on apoptosis of Daudi cells induced by monoclonal antibodies against human CD20. Immunol. J. 18:292–295, 2002.
Lilley, G. G., O. Dolezal, C. J. Hillyard, C. Bernard, and P. J. Hudson. Recombinant single-chain antibody peptide conjugates expressed in Escherichia coli for the rapid diagnosis of HIV. J. Immunol. Meth. 171:211–226, 1994.
Lofblöm, J., J. Sandberg, H. Wernérus, and S. Ståhl. Evaluation of staphylococcal cell surface display and flow cytometry for postselectional characterization of affinity proteins in combinatorial protein engineering applications. Appl. Environ. Microbiol. 73:6714–6721, 2007.
Loken, M. R., V. O. Shah, K. L. Datillio, and C. I. Civin. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 70:1316–1324, 1987.
Long, M., H. Zhao, K. S. Huang, and C. Zhu. Kinetic measurements of cell surface E-selectin/carbohydrate ligand interactions. Ann. Biomed. Eng. 29:935–946, 2001.
Petit, S., F. Brard, G. Coquerel, G. Perez, and F. Tron. Structural models of antibody variable fragments: a method for investigating binding mechanisms. J. Comput. Aid Mol. Des. 12:147–163, 1998.
Press, O. W., F. Appelbaum, J. A. Ledbetter, P. J. Martin, J. Zarling, P. Kidd, and E. D. Thomas. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584–591, 1987.
Schmiedl, A., J. Zimmermann, J. E. Scherberich, P. Fischer, and S. Dubel. Recombinant variants of antibody 138H11 against human gamma-glutamyltransferase for targeting renal cell carcinoma. Hum. Antibodies 15:81–94, 2006.
Selvaraj, P., M. L. Plunkett, M. Dustin, M. E. Sanders, S. Shaw, and T. A. Springer. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 326:400–403, 1987.
Shan, D. M., O. W. Press, T. T. Tsu, M. S. Hayden, and J. A. Ledbetter. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J. Immunol. 162:6589–6595, 1999.
Sheikholvaezin, A., P. Sandstrom, D. Eriksson, N. Norgren, K. Riklund, and T. Stigbrand. Optimizing the generation of recombinant single-chain antibodies against placental alkaline phosphatase. Hybridoma (Larchmt) 25:181–192, 2006.
Stashenko, P., L. M. Naler, R. Hardy, and S. F. Schlossman. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125:1678–1685, 1980.
Tedder, T. F., A. W. Boyd, A. S. Freedman, L. M. Nadler, and S. F. Schlossman. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J. Immunol. 135:973–979, 1985.
Tedder, T. F., and P. Engel. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15:450–454, 1994.
Thompson, J. D., D. G. Higgins, and T. Gibson. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. J. Nucleic Acids Res. 22:4673–4680, 1994.
Turner, D. J., M. A. Ritter, and A. J. George. Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. J. Immunol. Meth. 205:43–54, 1997.
van Gunsteren, W. F., and H. J. Berendsen. Computer simulation as a tool for tracing the conformational differences between proteins in solution and in the crystalline state. J. Mol. Biol. 176:559–564, 1984.
von Schilling, C. Immunotherapy with anti-CD20 compounds. Semin. Cancer Biol. 13:211–222, 2003.
Wang, Y. G., Y. Huang, X. Gu, M. Yu, J. N. Feng, Y. X. Sun, Y. Li, and B. F. Shen. Construction and expression of chimeric anti-human CD20 monoclonal antibody. J. Cell. Mol. Immunol. 22:363–367, 2006.
Wang, S. H., J. B. Zhang, Z. P. Zhang, Y. F. Zhou, R. F. Yang, J. Chen, Y. C. Guo, F. You, and X. E. Zhang. Construction of single chain variable fragment (ScFv) and BiscFv-alkaline phosphatase fusion protein for detection of Bacillus anthracis. Anal. Chem. 78:997–1004, 2006.
Wu, L., B. T. Xiao, X. L. Jia, Y. Zhang, S. Q. Lü, J. Chen, and M. Long. Impacts of carrier stiffness and microtopology on 2D kinetics of P-selectin-PSGL-1 interactions. J. Biol. Chem. 282:9846–9854, 2007.
Acknowledgments
We thank Periasamy Selvaraj of Emory University School of Medicine for generous gifts of TS 2/9 mAb. This work was supported by National High Technology Research and Development Program of China Grant 2007AA02Z306, National Key Basic Research Foundation of China Grant 2006CB910303, National Natural Science Foundation of China Grants 30730032, 30771982 and 10332060, and Knowledge Innovation Program of Chinese Academy of Sciences Grant KJCX2-YW-L08 (M.L.), as well as National High Technology Research and Development Program of China Grant 2006AA02A254 and Beijing Grant 5062037 (Y.L.).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Xin Gu, Xiaoling Jia, and Jiannan Feng contributed equally to this work.
Rights and permissions
About this article
Cite this article
Gu, X., Jia, X., Feng, J. et al. Molecular Modeling and Affinity Determination of scFv Antibody: Proper Linker Peptide Enhances Its Activity. Ann Biomed Eng 38, 537–549 (2010). https://doi.org/10.1007/s10439-009-9810-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10439-009-9810-2